BCL2 and B-cell chronic lymphocytic leukemia: CLL cells under this protective condition were less sensitive to the Bcl-2 inhibitor venetoclax, as shown by an averaged 6-fold increase in the mean IC50 from 0.007 μM to 0.042 μM (Fig. 4C).